Ajay Kumar Steps Down as Independent Director from Cyient DLM Board
Hyderabad, May 15 (UN I) Hyderabad-based Cyient DLM, an integrated partner for design-led manufacturing, on Thursday announced that Dr. Ajay Kumar has stepped down from the position of Independent Director on the Board of Directors of the Company.
Dr. Kumar's resignation follows his recent appointment as Chairman of the Union Public Service Commission (UPSC), a prestigious position bestowed by the President of India, the company said in a release here.
Dr. Kumar also relinquishes his responsibilities as a member of the Nomination and Remuneration Committee and the Stakeholder Relationship Committee of the Board with immediate effect.
Dr. Kumar joined the Cyient DLM Board with a wealth of experience and exceptional insight, particularly in defence, strategic planning and governance.
During his tenure, he made invaluable contributions to the company's long-term vision and operational excellence.
Commenting on the development, Krishna Bodanapu, Chairman, Cyient DLM, said, 'We are grateful to Dr. Ajay Kumar for his outstanding service as an Independent Director on our Board. His invaluable counsel and deep expertise will continue to inspire and guide us. His contributions have left a lasting impact. On behalf of the entire Board and the company, I extend our heartfelt thanks and best wishes as he embarks on his journey as Chairman of the UPSC.'
UNI KNR BD
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
an hour ago
- Mint
Why 125+ CFOs have resigned in Q1. Hint: it's personal
Mumbai: More than 125 chief financial officers (CFOs) have exited listed companies in the first three months of FY26 — a sharp 25% jump from a year earlier — as per disclosures made to the BSE. Some of them walked out overnight, citing a cryptic phrase, 'personal reasons'. The sudden resignation last Monday of Mastek Ltd's CFO Raghavendra Jha, barely a month into the job, is the latest in a string of such departures. In a one-line email addressed to the company's chief executive, Jha said he was putting in his papers due to personal reasons, without providing any other detail. Such exits have cast doubts about corporate governance and regulatory compliance. When a listed company's key managerial personnel, including CFOs, resign, they are required to provide a detailed reason for their departure, as per the listing obligations and disclosure requirements of market regulator Securities and Exchange Board of India (Sebi). Experts said the KMPs are merely ticking the box in terms of complying with this requirement by citing vague reasons when resigning. 'The abrupt resignation of key managerial personnel, especially CFOs, often signals deeper issues within a company," said V. Balakrishnan, a former CFO at IT services major Infosys Ltd and founder of Exfinity Ventures, a venture capital fund. 'While regulators require disclosure of resignation reasons, the frequent use of vague terms like 'personal reasons' has become a convenient cover." Balakrishnan pointed out that in several instances, irregularities at companies have surfaced shortly after such exits. For example, Ankit Jain, the former CFO of Gensol Engineering, resigned in early March citing personal reasons and pursuit of other professional avenues as the reason for his departure. A month later, Sebi released its interim order against the company and its promoters, disclosing severe lapses in governance and diversion of funds. Similarly, IndusInd Bank's former CFO Gobind Jain's resignation this January was followed in March by the bank disclosing that it had financial discrepancies of over ₹2,000 crore in its derivatives portfolio. Jain had cited personal travel to the US and pursuit of other career opportunities as the reason for his exit. 'This raises serious concerns and strengthens the case for Sebi to broaden the disclosure mandate," said Balakrishnan. 'The onus must be on the board to reconcile these stated reasons with any financial lapses discovered later, and to be held accountable for any oversight or complicity." Currently, Ankit Jain is the CFO of SB-Constantia Flexibles, a joint venture between Constantia, an Austrian firm, and SB Packagings, a Delhi-based packaging firm. To be sure, in most cases when executives resign citing personal reasons, they end up joining a different firm. The pursuit of another career is the second most-cited reason for exits. However, experts say that the ambiguity created by this term allows even cases where there are serious issues at the firm to pass under the radar. Shriram Subramanian, a corporate governance expert and managing director of proxy advisory firm InGovern, said boards need to be cognizant that they are working in the interest of shareholders. 'If there is any other reason for the resignation like fraud or disciplinary action, they should disclose as much to the exchanges instead of letting it slide as 'personal reason'," he said. Meanwhile, Mumbai-headquartered IT services company Mastek, which ended FY25 with $408.4 million in revenue and is valued at $890 million, said there were no governance concerns behind CFO Jha's resignation in just over a month of joining. Jha did not respond toMint's messages requesting comment. 'We are not happy with having two CFOs in the last six months; it creates a wrong impression," said Ashank Desai, the company's chairman. Last December, Arun Agarwal had resigned as CFO after serving in the role for just over four years. 'Mastek stands for the highest corporate governance. I can vouch for it," said Desai, who co-founded the company in 1982.
Time of India
an hour ago
- Time of India
Trichy corpn fixes rent for Panjapur truck terminal shops
Trichy: In its monthly meeting on Monday, the Trichy Corporation passed a resolution setting rent and deposit rates for shops at the Panjapur truck terminal, located on the Trichy-Madurai National Highway near the Integrated Bus Terminus (IBT). The local body has requested support from the Trichy city police to enforce the diversion of trucks and heavy vehicles currently parked on city highways and service roads to the new terminal. The council was informed that the terminal has 51 shops on the ground floor and 28 shops-cum-office spaces on the first floor. Rent has been fixed at Rs 132 per square foot, following government guidelines, while deposits range from Rs 4 lakh to Rs 10 lakh, depending on shop size (250 to 1,001 sq ft). The shops and amenities, including dormitories and sanitary complexes, will be leased out through a tender process. CPI councillor K Suresh emphasized the importance of police cooperation, stating, "If trucks parked on city roads are not regulated and diverted to the terminal, the project will fail." Councillors highlighted ongoing issues with truck parking on East Boulevard Road and near Gandhi Market, which cause significant traffic congestion due to poor enforcement. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Uber luxury living at Hyderabad's billionaire junction Sumadhura Group Learn More Undo Mayor Mu Anbalagan assured that police would be directed to streamline on-street truck parking and ensure vehicles are redirected to the Panjapur terminal. The meeting also approved 53 resolutions, including a 10% hike in the annual outsourcing cost for solid waste collection awarded to Pudukkottai-based S R United Infra Developers, a decision that drew criticism from several councillors. They also urged the corporation to consider wage revisions for sanitary workers. With the monsoon approaching, Congress councillor L Rex and MMK councillor Faiz Ahamed requested funds to maintain major drains in their respective wards. Truck Terminal, Panjapur Cost: Rs 110.9 crore Area: 13 acres Capacity: Two-axle trucks: 231 Three and four-axle trucks: 10 Five and six-axle trucks: 5 Total: 246 Shops: 79 Rent: Rs 132 per square foot Deposits: Rs 4-10 lakh
Economic Times
an hour ago
- Economic Times
Wockhardt activates Zaynich push, eyes global licensing deals
Habil Khorakiwala Mumbai: Wockhardt is working on ambitious plans for Zaynich, a combination of zidebactam and cefepime that was found to be effective during clinical trials to fight superbugs or bacterial infections that show resistance to a range of existing antibiotic treatments. The drug maker has hired merchant bankers to identify possible out-licensing deals for the novel product, chairman Habil Khorakiwala told ET in an exclusive interview. Wockhardt in March sought regulatory approval for Zaynich in India and expects its commercial launch in the first half of '26. In the US, it plans to file for regulatory clearance in August.'We will get into the US market by the end of FY26 or latest by the second half of 2026 and Europe will be a year later,' Khorakiwala said. Zaynich is seen as a game-changing drug against drug-resistant gram-negative pathogens. These pathogens are difficult to kill. Zaynich is estimated to have a market opportunity of about $9 billion. Around a million people die due to multidrug resistance in India every year, while worldwide, the number is 5 million, Khorakiwala said. Currently there are very few effective treatments available for these infections. Mumbai-based Wockhardt completed the Phase-3 clinical trials for Zaynich earlier this year. In January it announced that the drug demonstrated more than 97% clinical efficacy in treating serious infections of bacteria resistant to carbapenem antibiotics, which are often used as a last resort to treat severe infections. The company is prepared to go solo to market Zaynich in India, the US and other markets if the licensing proposals do not meet its expectations on valuation, Khorakiwala said without revealing the valuation he is looking for.'We will evaluate how to go about and take an appropriate call, so we are keeping two options fully alive,' Khorakiwala said. 'One option is licensing out, the other is in some markets like in India we are doing ourselves,' he said. 'The US is another market where we are thinking of the possibility (of marketing on its own); you don't need too much marketing cost and you have talent available.'Wockhardt also plans to fully outsource manufacturing for the Western markets to eliminate issues related to the US Food and Drug Administration, and channel its focus on the clinical and research part.'For manufacturing, plenty of options are available in Europe and the US, so I am not getting into FDA-related manufacturing problems,' said Khorakiwala. 'Zaynich — we are manufacturing everything in Europe.' It will adopt the same strategy to outsource most of the manufacturing for all its other new company had in the past faced some issues with the US FDA over alleged violations of good manufacturing practices. 'That (FDA-elated manufacturing problems) was our weakness, and I am eliminating that completely from my western markets to only focus on the clinical and research part,' he said. COMPANY TURNAROUND Wockhardt has seen a remarkable turnaround in its stock price in the past year and a half with renewed confidence from investors, with developments on Zaynich being among the key drivers. Its stock price more than doubled in the last 12 months and increased over three-and-a-half times since January 2024. The shares closed at `1,713.20, up 4.5%, on BSE Monday. 'We have revisited what are the strengths and what are the opportunities — one obviously is our new drug discovery — in India and worldwide,' said also stressed on the company's focus on biologics as another key growth driver.'Within biologics we will stay in insulin and GLP1; we are not going to touch the rest of the biologics like monoclonal antibodies and others. Because we feel it is important to be focused,' he does not see itself as a generic company, he said. 'In fact, in the US we are exiting generics … we will be focused on the biological area and NCE (new chemical entities) and strictly on antibiotics,' he chairman said his research pipeline has a range of antibiotics under development, including early-stage work on an oral version of Zaynich. PRICING STRATEGY Khorakiwala said the treatment cost with most new products including antimicrobials launched in the last 10 years in the US has been in the range of $10,000-15,000 per treatment. Zaynich will also hover in that range in the US but in India, the price will be significantly lower, he said.
